## Andrew Lees

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6400904/publications.pdf

Version: 2024-02-01



ANDREWLEES

#	Article	IF	CITATIONS
1	T Cell-Independent Antigens Type 2. Annual Review of Immunology, 1995, 13, 655-692.	21.8	778
2	Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein—polysaccharide conjugate vaccines and immunological reagents. Vaccine, 1996, 14, 190-198.	3.8	124
3	Salmonella enterica Serovar Enteritidis Core O Polysaccharide Conjugated to H:g,m Flagellin as a Candidate Vaccine for Protection against Invasive Infection with <i>S.</i> Enteritidis. Infection and Immunity, 2011, 79, 4240-4249.	2.2	114
4	A Cryptococcal Capsular Polysaccharide Mimotope Prolongs the Survival of Mice with <i>Cryptococcus neoformans</i> Infection. Journal of Immunology, 2001, 166, 1087-1096.	0.8	105
5	Differential Regulation of IgG Anti-Capsular Polysaccharide and Antiprotein Responses to IntactStreptococcus pneumoniaein the Presence of Cognate CD4+T Cell Help. Journal of Immunology, 2004, 172, 532-539.	0.8	86
6	Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides. Vaccine, 2000, 18, 1273-1281.	3.8	67
7	Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa. PLoS ONE, 2018, 13, e0203143.	2.5	67
8	Immunogenicity and Efficacy of Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice. Infection and Immunity, 2004, 72, 196-208.	2.2	59
9	A Peptide Mimotope of Type 8 Pneumococcal Capsular Polysaccharide Induces a Protective Immune Response in Mice. Infection and Immunity, 2005, 73, 325-333.	2.2	51
10	Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotide motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion. International Immunology, 1999, 11, 1693-1700.	4.0	48
11	Enhanced Protective Antibody Responses to PspA after Intranasal or Subcutaneous Injections of PspA Genetically Fused to Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2. Infection and Immunity, 1998, 66, 1513-1520.	2.2	48
12	B7 Requirements for Primary and Secondary Protein- and Polysaccharide-Specific Ig Isotype Responses toStreptococcus pneumoniae. Journal of Immunology, 2000, 165, 6840-6848.	0.8	46
13	Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa. PLoS Neglected Tropical Diseases, 2017, 11, e0005493.	3.0	44
14	Therapeutic Efficacy of a Conjugate Vaccine Containing a Peptide Mimotope of Cryptococcal Capsular Polysaccharide Glucuronoxylomannan. Vaccine Journal, 2008, 15, 1176-1187.	3.1	40
15	Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins. Molecular Pharmaceutics, 2018, 15, 4947-4962.	4.6	40
16	Mannan-Abeta28conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. Journal of Neuroinflammation, 2008, 5, 42.	7.2	35
17	Versatile and efficient synthesis of protein–polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry. Vaccine, 2006, 24, 716-729.	3.8	33
18	A scalable method for biochemical purification of Salmonella flagellin. Protein Expression and Purification, 2014, 102, 1-7.	1.3	31

ANDREW LEES

#	Article	IF	CITATIONS
19	Analytical Comparability Assessments of 5 Recombinant CRM 197 Proteins From Different Manufacturers and Expression Systems. Journal of Pharmaceutical Sciences, 2018, 107, 1806-1819.	3.3	31
20	Parameters Underlying Distinct T Cell-Dependent Polysaccharide-Specific IgG Responses to an Intact Gram-Positive Bacterium versus a Soluble Conjugate Vaccine. Journal of Immunology, 2009, 183, 1551-1559.	0.8	29
21	Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules. Vaccine, 1994, 12, 1160-1166.	3.8	27
22	The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity. Cellular Immunology, 2004, 232, 64-74.	3.0	27
23	Aβ-Immunotherapy for Alzheimer's Disease Using Mannan–Amyloid-Beta Peptide Immunoconjugates. DNA and Cell Biology, 2006, 25, 571-580.	1.9	27
24	Exploiting molecular mimicry to broaden the immune response to carbohydrate antigens for vaccine development. Vaccine, 2001, 19, 2361-2368.	3.8	23
25	B-cell–T-cell activation and interaction in common variable immunodeficiency. Human Immunology, 2010, 71, 355-362.	2.4	22
26	Immunogenicity and Induction of Functional Antibodies in Rabbits Immunized with a Trivalent Typhoid-Invasive Nontyphoidal Salmonella Glycoconjugate Formulation. Molecules, 2018, 23, 1749.	3.8	22
27	Monoclonal antibodies to distinct regions of human myelin proteolipid protein simultaneously recognize central nervous system myelin and neurons of many vertebrate species. Journal of Neuroscience Research, 2006, 83, 415-431.	2.9	19
28	The Nature of an In Vivo Anti-Capsular Polysaccharide Response Is Markedly Influenced by the Composition and/or Architecture of the Bacterial Subcapsular Domain. Journal of Immunology, 2012, 188, 569-577.	0.8	16
29	Novel Synthetic (Poly)Clycerolphosphate-Based Antistaphylococcal Conjugate Vaccine. Infection and Immunity, 2013, 81, 2554-2561.	2.2	16
30	Intact Bacteria Inhibit the Induction of Humoral Immune Responses to Bacterial-Derived and Heterologous Soluble T Cell-Dependent Antigens. Journal of Immunology, 2009, 182, 2011-2019.	0.8	15
31	Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230. Vaccine, 2020, 38, 5480-5489.	3.8	15
32	Characterization of Early Activation Events in Cord Blood B Cells after Stimulation with T Cell-Independent Activators. Pediatric Research, 1998, 43, 496-503.	2.3	15
33	Enhanced and sustained activation of human B cells by anti-immunoglobulin conjugated to the EBV glycoprotein gp350. European Journal of Immunology, 2000, 30, 969-973.	2.9	13
34	Evidence of a Functional B-Cell Immunodeficiency in Adults Who Experience Serogroup C Meningococcal Disease. Vaccine Journal, 2009, 16, 692-698.	3.1	11
35	Functional T-Cell Deficiency in Adolescents Who Experience Serogroup C Meningococcal Disease despite Receiving the Meningococcal Serogroup C Conjugate Vaccine. Vaccine Journal, 2010, 17, 1104-1110.	3.1	10
36	Rapid and complete adsorption of unconjugated protein from protein-polysaccharide conjugate vaccines. Vaccine, 2001, 19, 1547-1558.	3.8	9

ANDREW LEES

#	Article	IF	CITATIONS
37	Activation of Soluble Polysaccharides with 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP) for Use in Protein–Polysaccharide Conjugate Vaccines and Immunological Reagents. III Optimization of CDAP Activation. Vaccines, 2020, 8, 777.	4.4	8
38	Harnessing galactose oxidase in the development of a chemoenzymatic platform for glycoconjugate vaccine design. Journal of Biological Chemistry, 2021, , 101453.	3.4	8
39	Immunization of cows with novel core glycolipid vaccine induces anti-endotoxin antibodies in bovine colostrum. Vaccine, 2014, 32, 6107-6114.	3.8	7
40	Adult Survivors of Invasive Pneumococcal Disease Exhibit Defective B Cell Function. Clinical Infectious Diseases, 2011, 52, 1133-1136.	5.8	5
41	Correlation of Group C Meningococcal Conjugate Vaccine Response with B- and T-Lymphocyte Activity. PLoS ONE, 2012, 7, e31160.	2.5	3
42	Conjugation Chemistry. , 0, , 161-174.		2
43	Adults with a history of serogroup c neisseria meningitidis disease exhibit impaired in vitro immune responses. Journal of Infection, 2008, 56, 300-301.	3.3	0
44	A Rapid Opsonic Assay for Measuring Killing of Bioluminescent <i>Staphylococcus epidermidis</i> . Hybridoma, 2008, 27, 487-491.	0.4	0
45	Contactâ€dependent suppression of <scp>CD</scp> 4 Tâ€cell activation and proliferation by B cells activated through IgD crossâ€linking. Immunology, 2015, 144, 444-452.	4.4	Ο